Phio Pharmaceuticals Corp. (PHIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
411 Swedeland Road
Marlborough, PA 19406
United States of America (the)
Phone
508 767 3861
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
May 10, 2012
| Name | Title | Pay | Year Born |
| Robert J. Bitterman | President, Chief Executive Officer & Chairman | 579,432 | 1951 |
| Lisa Carson | CFO, Principal Accounting Officer and VP of Finance & Administration | 371,370 | 1967 |
| Jennifer Phillips | Senior Vice President of Regulatory & Corporate Affairs | 0 | N/A |
| Linda Mahoney | Senior Vice President of Development | 0 | N/A |
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.